Current Report Filing (8-k)
November 15 2017 - 08:59AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): October 31, 2017
OWC
PHARMACEUTICAL RESEARCH CORP.
(Exact Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware
|
|
98-0573566
|
(State of
Incorporation)
|
|
(I.R.S. Employer
Identification No.)
|
30 Shacham Street.
P.O.B. 8324 Petach Tikva, Israel
|
|
4918103
|
(Address of Principal
Executive Offices)
|
|
(ZIP Code)
|
Registrant’s
Telephone Number, including area code: 972 (0) 3-758-2657
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
October 31, 2017, OWC Pharmaceutical Research Corp. (OTCQB: OWCP), hereinafter, the “Registrant”), appointed Ms. Hannah
Feuer to serve as a member of the Board of Directors of the Registrant and Chairman of the Registrant’s Audit Committee.
Ms.
Hannah Feuer, Age 62, Director and Chairman of the Audit Committee:
Ms. Feuer is a CPA and Senior CFO with more than 20 years
of experience in capital markets and management in financial institutions. During Ms. Feuer’s professional career, she has
developed significant expertise working with boards of directors of both financial institutions and major companies and has extensive
knowledge of public offerings and underwriting, as well as raising and managing private equity funds. In depth knowledge of operational
management, including procurement and human resources. Since 2003, Ms. Feuer has served as group CFO of Poalim Capital Markets,
one of Israel’s leading investment banks and a subsidiary of Bank Hapoalim, Israel’s largest financial group. She
has also served as an independent director at Negev Ceramics Ltd from 2007 to 2012, prior to which Ms. Feuer served as a director
at Bagir Ltd. from 2007 to 2009.
Ms
Feuer received her B.A. degree in Accounting and Economics from the University of California State Northridge in 1983 and B.A.
degree with Honors in Sociology from the University of Tel Aviv, Israel in 1980.
Item
8.01. Other Events.
On
November 8, 2018, the Registrant was granted a Certificate of Patent, #2015101908 (the “Innovation Patent”) from the
Commissioner of Patents, Commonwealth of Australia, for the Registrant’s proprietary cream for the treatment of skin disorders.
The Registrant’s skin cream has been proven, pre-clinically, to lower various inflammatory markers by up to 70% and to inhibit
Keratocytes proliferation, a manifestation of various skin disorders, especially Psoriasis. A human safety study for the OWC cream
is currently ongoing. We believe that the Innovation Patent granted in Australia, valid for a term of 8 years, should be followed
by additional patent grants in other jurisdictions and should afford protection and competitive advantage to the Registrant, subsequent
to efficacy trials to be performed in 2018, to manufacture, distribute and sell our cannabis based products wherever there exists
a lawful medical cannabis market.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
OWC Pharmaceutical Research Corp.
|
|
|
|
|
|
/s/
Mordechai Bignitz
|
|
Name:
|
Mordechai Bignitz
|
|
Title:
|
Chief Executive
Officer
|
|
Date:
November 15, 2017
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Feb 2024 to Mar 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Mar 2023 to Mar 2024
Real-Time news about OWC Pharmaceuticals Research Corporation (CE) (OTCMarkets): 0 recent articles
More Owc Pharmaceutical Research Corp. News Articles